Press releases

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Novimmune SA announced the presentation of late-breaking data from the phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) at the 2019 Transplantation and Cellular...

02/26/2019 - 09:00

Save the date for Swedish Orphan Biovitrum AB (publ) (Sobi™) Capital Markets Day on 14 May 2019. The event will take place at Karolinska Institutet Biomedicum, Solnavägen 9, Solna, from 12:30 – 16:30. A lighter lunch will be served at 11:30. We also welcome all...

02/21/2019 - 13:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the results for the fourth quarter and full-year 2018. Total revenues grew 37 per cent compared with Q4 2017 (29 per cent at constant exchange rates (CER)) and amounted to SEK 2,571 M. EBITA was SEK 916 M, an...

02/20/2019 - 08:00
Regulatory

On 20 February, at 08:00 CET, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full year 2018. Financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the...

02/11/2019 - 14:30

Sobi™ will present data at the European Association of Haemophilia and Allied Disorders (EAHAD) conference in Prague, Czech Republic, 6-8 February 2019, showing evidence on the safety, efficacy and long-term benefits of its extended half-life products for the treatment...

02/07/2019 - 09:00

Press contacts

Subscribe to our press releases and financial reports